Axsome Therapeutics, Inc. (AXSM)

Market Cap	7.98B +29.5%
Revenue (ttm)	638.50M +65.5%
Net Income	-183.17M
EPS	-3.68
Shares Out	51.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	854,164
Open	154.55
Previous Close	154.12
Day's Range	153.67 - 157.75
52-Week Range	86.99 - 191.50
Beta	0.49
Analysts	Strong Buy
Price Target	209.18 (+34.02%)
Earnings Date	May 4, 2026

About AXSM

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 19, 2015
• Employees: 925
• Stock Exchange: NASDAQ
• Ticker Symbol: AXSM
• Website: https://www.axsome.com

Financial Performance

In 2025, Axsome Therapeutics's revenue was $638.50 million, an increase of 65.55% compared to the previous year's $385.69 million. Losses were -$183.17 million, -36.22% less than in 2024.

Analyst Summary

According to 17 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price target is $209.18, which is an increase of 34.02% from the latest price.

Price Target

$209.18

(34.02% upside)

Analyst Consensus: Strong Buy